Natera v. CareDx: cfDNA Transplant Monitoring Patent Dispute Consolidated in Delaware
Natera, Inc. asserted US10655180B2 — covering cell-free DNA methods for organ transplant monitoring — against CareDx’s AlloSure, AlloSeq, KidneyCare and HeartCare products. After 1,034 days, Case No. 1:22-cv-00641 was consolidated with two related actions under lead case 1:22-cv-00038 before Judge Colm F. Connolly in the District of Delaware.
Natera’s cfDNA Transplant Patent Claims Channelled into Single Delaware Action
On 13 May 2022, Natera, Inc. filed Case No. 1:22-cv-00641 in the United States District Court for the District of Delaware, alleging that CareDx, Inc. infringed US10655180B2. The patent, filed under application number US16/353636, covers cell-free DNA (cfDNA) methods used to monitor organ transplant recipients for signs of rejection. The accused products included CareDx’s AlloSure kidney transplant monitoring product, as well as its AlloSeq, KidneyCare and HeartCare product lines — a portfolio spanning kidney and heart transplant diagnostics.
The case did not reach a merits adjudication in its own docket. On 12 March 2025, pursuant to Federal Rule of Civil Procedure 42(a), the court consolidated Case No. 1:22-cv-00641 together with related actions 1:22-cv-00038 and 1:22-cv-00642 for all purposes, including trial. The -038 action was designated the lead case, and all future filings were directed to that docket. Consolidation under Rule 42(a) reflects the court’s determination that the actions share common questions of law or fact sufficient to warrant unified management.
The 1,034-day duration before consolidation suggests the parties engaged in substantial pre-trial activity — discovery, claim construction, and potentially dispositive motions — across the parallel dockets before the court imposed unified management. The public record for this case number is silent on whether any substantive rulings were entered prior to consolidation. The operative battleground now shifts entirely to lead case 1:22-cv-00038, where the ultimate merits of Natera’s cfDNA patent assertions against CareDx’s transplant diagnostics portfolio will be resolved.
Filing to Case Consolidated in 1034 days
1,034 days from filing to consolidation — consistent with complex multi-action patent disputes in Delaware
Rule 42(a) consolidation: what it means for both parties going forward
Rule 42(a) consolidation merges cases with common questions
Federal Rule of Civil Procedure 42(a) permits a court to consolidate actions that share common questions of law or fact. Here, the court consolidated three related Natera v. CareDx actions — 1:22-cv-00038, 1:22-cv-00641, and 1:22-cv-00642 — into a single proceeding for all purposes including trial. This is a procedural efficiency measure, not a merits ruling; no party wins or loses at consolidation.
Procedural — no merits rulingNatera advances all patent claims in a single, coordinated action
Consolidation is broadly neutral-to-favourable for a plaintiff asserting a common patent portfolio across multiple actions. Natera can now pursue all infringement claims against CareDx’s transplant diagnostics products in one coordinated proceeding, reducing duplicative litigation costs and the risk of inconsistent rulings. The substantive strength of US10655180B2 and any related patents in the -038 lead case will determine the ultimate outcome.
Unified enforcement postureCareDx faces consolidated invalidity and non-infringement challenge
For CareDx, consolidation means its defences across all accused products — AlloSure, AlloSeq, KidneyCare and HeartCare — must be coordinated and presented in the -038 lead case. While this reduces parallel litigation burden, it also concentrates risk: an adverse merits ruling in the lead case would resolve all three actions simultaneously. CareDx’s invalidity and non-infringement arguments now carry higher strategic stakes.
Concentrated defence riskTransplant diagnostics IP landscape awaits lead case resolution
The outcome of the consolidated -038 action will be highly material to the competitive dynamics between cfDNA-based transplant monitoring platforms. CareDx’s AlloSure product holds significant market position in kidney transplant surveillance; a finding of infringement or invalidity of Natera’s US10655180B2 would send a clear signal about freedom-to-operate for cell-free DNA diagnostic developers across the organ transplant sector.
High-stakes for cfDNA diagnostics sectorFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Natera, Inc. | Company | Transplant genomics company — holder of US10655180B2 covering cfDNA transplant monitoring methodsSearch in Eureka ↗ |
| Defendant | CareDx, Inc. | Company | CareDx, Inc. — transplant diagnostics company offering AlloSure, AlloSeq, KidneyCare and HeartCare productsSearch in Eureka ↗ |
| Plaintiff counsel | Anthony David Raucci | Attorney | Counsel for Natera, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Derek James Fahnestock | Attorney | Counsel for Natera, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Jack B. Blumenfeld | Attorney | Counsel for Natera, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Morris, Nichols, Arsht & Tunnell LLP | Law Firm | Representing Natera, Inc.Search in Eureka ↗ |
| Defendant counsel | Michael J. Farnan | Attorney | Counsel for CareDx, Inc.Search in Eureka ↗ |
| Defendant law firm | Farnan LLP | Law Firm | Representing CareDx, Inc.Search in Eureka ↗ |
| Presiding judge | Judge Colm F. Connolly | Judge | Delaware District CourtSearch in Eureka ↗ |
Official order — verbatim text
The consolidation order invokes Rule 42(a) to merge three related Natera v. CareDx actions for all purposes including trial, designating 1:22-cv-00038 as the lead case. This is a purely procedural disposition — no liability finding, no claim construction, and no ruling on validity or infringement has been issued under this case number. The practical effect is that the merits of Natera’s assertions under US10655180B2, and CareDx’s defences across its AlloSure, AlloSeq, KidneyCare and HeartCare products, will now be determined exclusively in the -038 lead action.
US10655180B2 — Cell-Free DNA Methods for Organ Transplant Rejection Monitoring
US10655180B2 was filed under application number US16/353636 and covers methods of using cell-free DNA (cfDNA) — genetic material shed by dying cells into the bloodstream — to non-invasively monitor organ transplant recipients for signs of rejection. The technology enables clinicians to detect donor-derived cfDNA elevations as a biomarker for allograft injury, offering an alternative to invasive biopsy. This positions the patent squarely within the high-growth field of liquid biopsy diagnostics applied to transplant medicine.
The commercial significance of US10655180B2 is underscored by the breadth of CareDx products accused of infringement: AlloSure (kidney), AlloSeq, KidneyCare and HeartCare span both kidney and cardiac transplant monitoring. Natera’s enforcement campaign suggests the patent is being deployed as a foundational barrier in the cfDNA transplant monitoring market. For competitors and new entrants developing cfDNA-based diagnostic platforms — particularly those targeting transplant rejection surveillance — this patent represents a significant freedom-to-operate consideration that requires careful claim mapping.
Should you run an FTO analysis against US10655180B2?
Any company developing, commercialising or investing in cell-free DNA diagnostic products for organ transplant monitoring — kidney, heart, liver or lung — should treat US10655180B2 as a priority FTO target. The breadth of CareDx products accused under this single patent (spanning kidney and cardiac diagnostics) suggests Natera is asserting wide claim coverage. R&D teams designing cfDNA extraction, quantification or donor-derived fraction analysis workflows for transplant applications should assess whether their methods fall within the asserted claims before market entry.
PatSnap Eureka’s FTO Search Agent can rapidly map the claims of US10655180B2 against your product’s technical workflow, identify prior art that may limit claim scope, and surface related Natera patents in the same family. Eureka also monitors the -038 lead case docket in real time, so your IP team receives alerts on claim construction orders, summary judgment rulings and trial outcomes as they occur — keeping your FTO assessment current as the litigation evolves.
Run a freedom-to-operate analysis on US10655180B2 to assess your product’s exposure
Run FTO in Eureka →Similar cfDNA Transplant Diagnostics Patent Cases in Delaware District Court
Explore related cell-free DNA transplant monitoring patent disputes litigated in Delaware District Court, including parallel Natera v. CareDx actions and comparable liquid biopsy enforcement cases.
What this case signals for the transplant diagnostics IP landscape
Multi-front cfDNA patent litigation in Delaware suggests both parties view the transplant monitoring market as worth sustained, high-cost legal contest.
Three parallel Delaware actions signals a serious, multi-patent enforcement campaign
Natera filing three related cases simultaneously — later consolidated under Rule 42(a) — is consistent with a coordinated enforcement strategy designed to assert maximum coverage across CareDx’s transplant diagnostics portfolio. Companies in the cfDNA space should monitor the -038 lead case closely as a bellwether for the enforceability of next-generation transplant monitoring patents.
AlloSure and cfDNA-based transplant monitoring face sustained patent exposure
CareDx’s AlloSure kidney and heart transplant products are named directly in the consolidated actions. Any adverse ruling on US10655180B2 in the lead case could constrain product development, labelling, and commercial positioning across CareDx’s entire transplant monitoring platform — a material business risk for a company whose revenue is concentrated in these diagnostic lines.
Natera v CareDx — key questions answered
Case No. 1:22-cv-00641 was consolidated under Federal Rule of Civil Procedure 42(a) with related actions 1:22-cv-00038 and 1:22-cv-00642 on 12 March 2025. The -038 action was designated the lead case. No merits ruling — on infringement, validity, or damages — was issued under this case number. All future proceedings occur in the -038 docket before Judge Colm F. Connolly in the District of Delaware.
Natera asserted US10655180B2 (application no. US16/353636), a patent covering cell-free DNA methods for monitoring organ transplant recipients for rejection. The accused CareDx products included AlloSure (kidney transplant monitoring), AlloSeq, KidneyCare and HeartCare — covering both kidney and cardiac transplant diagnostics.
Rule 42(a) consolidation merges cases sharing common questions of law or fact into a single proceeding for efficiency. Here, three related Natera v. CareDx actions were consolidated for all purposes including trial under lead case 1:22-cv-00038. It is a procedural step only — no party wins or loses at this stage. The merits of infringement and validity will be decided in the -038 lead action.
The complaint in Case No. 1:22-cv-00641 named CareDx’s AlloSure product for kidney transplant recipients, as well as CareDx’s AlloSeq, KidneyCare and HeartCare products. These represent CareDx’s core transplant surveillance portfolio spanning kidney and cardiac indications.
The substantive litigation now proceeds under lead case 1:22-cv-00038 in the District of Delaware before Judge Colm F. Connolly. Key upcoming milestones to track include claim construction (Markman) proceedings, any summary judgment motions, and trial scheduling. PatSnap Eureka monitors the -038 docket and related patent family activity in real time.
PatSnap Eureka searches patents and litigation data to answer instantly.